Clinical trial
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once…
NCT00446602 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Withdrawn
Key facts
| NCT number | NCT00446602 |
|---|---|
| Title | A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) |
| Official title | A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Clinical Affairs, L.L.C. Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes, Anemia |
| Intervention type | Drug |
| Interventions | Epoetin alfa |
| Enrollment | 0 |
| Completion | Aug 1, 2009 |
| First posted | Mar 13, 2007 |
| Last update posted | Sep 20, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: